JNK3 inhibitors as promising pharmaceuticals with neuroprotective properties.
Yibeini WuYiling ZhaoZiman GuanSajjad EsmaeiliZhicheng XiaoDiji KuriakosePublished in: Cell adhesion & migration (2024)
The intensive study and investigation of neuroprotective therapy for central nervous system (CNS) diseases is ongoing. Due to shared mechanisms of neurodegeneration, a neuroprotective approach might offer benefits across multiple neurological disorders, despite variations in symptoms or injuries. C-Jun N-terminal Kinase 3 (JNK3) is found primarily in the CNS and is involved in physiological processes such as brain development, synapse formation, and memory formation. The potential of JNK3 as a target for pharmacological development holds promise for advancing neuroprotective therapies. Developing small molecule JNK3 inhibitors into drugs with neuroprotective qualities could facilitate neuronal restoration and self-repair. This review focuses on elucidating key neuroprotective mechanisms, exploring the interplay between neurodegenerative diseases and neuroprotection, and discussing advancements in JNK3 inhibitor drug development.
Keyphrases
- cerebral ischemia
- blood brain barrier
- subarachnoid hemorrhage
- signaling pathway
- cell death
- brain injury
- small molecule
- induced apoptosis
- oxidative stress
- risk assessment
- machine learning
- physical activity
- protein protein
- resting state
- big data
- functional connectivity
- tyrosine kinase
- sleep quality
- protein kinase
- drug induced